Pseudohypoparathyroidism, Albright's Hereditary Osteodystrophy, and Progressive Osseous Heteroplasia: Disorders Caused by Inactivating GNAS Mutations

Endocrinology: Adult and Pediatric

Volumn 1-2, Issue , 2015, Pages 1147-1159.e6

  Bastepe, Murat ^a   Jüppner, Harald ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85072144545     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-18907-1.00066-4     Document Type: Chapter

References (239)

1. Albright F., Burnett C.H., Smith P.H., Parson W. Pseudohypoparathyroidism-an example of "Seabright-Bantam syndrome.". Endocrinology 1942, 30:922-932.
2. Tashjian A.H., Frantz A.G., Lee J.B. Pseudohypoparathyroidism: assays of parathyroid hormone and thyrocalcitonin. Proc Natl Acad Sci U S A 1966, 56:1138-1142.
3. Ish-Shalom S., Rao L.G., Levine M.A., et al. Normal parathyroid hormone responsiveness of bone-derived cells from a patient with pseudohypoparathyroidism. J Bone Miner Res 1996, 11:8-14.
4. Murray T., Gomez Rao E., Wong M.M., et al. Pseudohypoparathyroidism with osteitis fibrosa cystica: direct demonstration of skeletal responsiveness to parathyroid hormone in cells cultured from bone. J Bone Miner Res 1993, 8:83-91.
5. Stone M., Hosking D., Garcia-Himmelstine C., et al. The renal response to exogenous parathyroid hormone in treated pseudohypoparathyroidism. Bone 1993, 14:727-735.
6. 2D synthesis in hypoparathyroidism and pseudohypoparathyroidism. Am J Physiol 1988, 255:E730-E736.
7. Drezner M.K., Neelon F.A., Haussler M., et al. 1,25-dihydroxycholecalciferol deficiency: the probable cause of hypocalcemia and metabolic bone disease in pseudohypoparathyroidism. J Clin Endocrinol Metab 1976, 42:621-628.
8. Braun J.J., Birkenhager J.C., Visser T.J., Juttmann J.R. Lack of response of 1,25-dihydroxycholecalciferol to exogenous parathyroid hormone in a patient with treated pseudohypoparathyroidism. Clin Endocrinol (Oxf) 1981, 14:403-407.
9. Yamaoka K., Seino Y., Ishida M., et al. Effect of dibutyryl adenosine 3',5'-monophosphate administration on plasma concentrations of 1,25-dihydroxyvitamin D in pseudohypoparathyroidism type I. J Clin Endocrinol Metab 1981, 53:1096-1100.
10. Drezner M.K., Haussler M.R. Normocalcemic pseudohypoparathyroidism. Association with normal vitamin D3 metabolism. Am J Med 1979, 66:503-508.
11. Balachandar V., Pahuja J., Maddaiah V.T., Collipp P.J. Pseudohypoparathyroidism with normal serum calcium level. Am J Dis Child 1975, 129:1092-1095.
12. Breslau N.A., Notman D.D., Canterbury J.M., Moses A.M. Studies on the attainment of normocalcemia in patients with pseudohypoparathyroidism. Am J Med 1980, 68:856-860.
13. Linglart A., Bastepe M., Jüppner H. Similar clinical and laboratory findings in patients with symptomatic autosomal dominant and sporadic pseudohypoparathyroidism type Ib despite different epigenetic changes at the GNAS locus. Clin Endocrinol (Oxf) 2007, 67:822-831.
14. Tamada Y., Kanda S., Suzuki H., et al. A pseudohypoparathyroidism type Ia patient with normocalcemia. Endocr J 2008, 55:169-173.
15. Jüppner H., Abou-Samra A.B., Freeman M.W., et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991, 254:1024-1026.
16. Gardella T.J., Jüppner H. Molecular properties of the PTH/PTHrP receptor. Trends Endocrinol Metab 2001, 12:210-217.
17. Abou-Samra A.B., Jüppner H., Force T., et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium. Proc Natl Acad Sci U S A 1992, 89:2732-2736.
18. Chase L.R., Melson G.L., Aurbach G.D. Pseudohypoparathyroidism: defective excretion of 3',5'-AMP in response to parathyroid hormone. J Clin Invest 1969, 48:1832-1844.
19. Drezner M., Neelon F.A., Lebovitz H.E. Pseudohypoparathyroidism type II: a possible defect in the reception of the cyclic AMP signal. N Engl J Med 1973, 289:1056-1060.
20. Siejka S.J., Knezevic W.V., Pullan P.T. Dystonia and intracerebral calcification: pseudohypoparathyroidism presenting in an eleven-year-old girl. Aust N Z J Med 1988, 18:607-609.
21. Dure L.S., Mussell H.G. Paroxysmal dyskinesia in a patient with pseudohypoparathyroidism. Mov Disord 1998, 13:746-748.
22. Huang C.W., Chen Y.C., Tsai J.J. Paroxysmal dyskinesia with secondary generalization of tonic-clonic seizures in pseudohypoparathyroidism. Epilepsia 2005, 46:164-165.
23. Prashantha D.K., Pal P.K. Pseudohypoparathyroidism manifesting with paroxysmal dyskinesias and seizures. Mov Disord 2009, 24:623-624.
24. Kinoshita M., Komori T., Ohtake T., et al. Abnormal calcium metabolism in myotonic dystrophy as shown by the Ellsworth-Howard test and its relation to CTG triplet repeat length. J Neurol 1997, 244:613-622.
25. Mahmud F.H., Linglart A., Bastepe M., et al. Molecular diagnosis of pseudohypoparathyroidism type Ib in a family with presumed paroxysmal dyskinesia. Pediatrics 2005, 115:e242-e244.
26. Bastepe M., Pincus J.E., Sugimoto T., et al. Positional dissociation between the genetic mutation responsible for pseudohypoparathyroidism type Ib and the associated methylation defect at exon A/B: evidence for a long-range regulatory element within the imprinted GNAS1 locus. Hum Mol Genet 2001, 10:1231-1241.
27. Unluturk U., Harmanci A., Babaoglu M., et al. Molecular diagnosis and clinical characterization of pseudohypoparathyroidism type-Ib in a patient with mild Albright's hereditary osteodystrophy-like features, epileptic seizures, and defective renal handling of uric acid. Am J Med Sci 2008, 336:84-90.
28. Windeck R., Menken U., Benker G., Reinwein D. Basal ganglia calcification in pseudohypoparathyroidism type II. Clin Endocrinol (Oxf) 1981, 15:57-63.
29. Chen H., Tseng F., Su D., et al. Multiple intracranial calcifications and spinal compressions: rare complications of type la pseudohypoparathyroidism. J Endocrinol Invest 2005, 28:646-650.
30. Illum F., Dupont E. Prevalences of CT-detected calcification in the basal ganglia in idiopathic hypoparathyroidism and pseudohypoparathyroidism. Neuroradiology 1985, 27:32-37.
31. Manabe Y., Araki M., Takeda K., et al. Pseudohypoparathyroidism with striopallidodentate calcification-a case report and review of the literature. Jpn J Med 1989, 28:391-395.
32. Pearson D.W., Durward W.F., Fogelman I., et al. Pseudohypoparathyroidism presenting as severe Parkinsonism. Postgrad Med J 1981, 57:445-447.
33. Saito H., Saito M., Saito K., et al. Subclinical pseudohypoparathyroidism type II: evidence for failure of physiologic adjustment in calcium metabolism during pregnancy. Am J Med Sci 1989, 297:247-250.
34. Zachariah S.B., Zachariah B., Antonios N., Prockop L.D. Pseudohypoparathyroidism and cerebrovascular disease with dural calcification. J Fla Med Assoc 1991, 78:26-28.
35. Narang M., Salota R., Sachdev S.S. Neonatal pseudohypoparathyroidism. Indian J Pediatr 2006, 73:97-98.
36. Sajitha S., Krishnamoorthy P.N., Shenoy U.V. Psedohypoparathyroidism in newborn-a rare presentation. Indian Pediatr 2003, 40:47-49.
37. Tsang R., Venkataraman P., Ho M., et al. The development of pseudohypoparathyroidism. Involvement of progressively increasing serum parathyroid hormone concentrations, increased 1,25-dihydroxyvitamin D concentrations, and "migratory" subcutaneous calcifications. Am J Dis Child 1984, 138:654-658.
38. Barr D.G., Stirling H.F., Darling J.A. Evolution of pseudohypoparathyroidism: an informative family study. Arch Dis Child 1994, 70:337-338.
39. Linglart A., Gensure R.C., Olney R.C., et al. A Novel STX16 deletion in autosomal dominant pseudohypoparathyroidism type Ib redefines the boundaries of a cis-acting imprinting control element of GNAS. Am J Hum Genet 2005, 76:804-814.
40. Gelfand I.M., Eugster E.A., Dimeglio L.A. Presentation and clinical progression of pseudohypoparathyroidism with multi-hormone resistance and Albright hereditary osteodystrophy: A case series. J Pediatr 2006, 149:877-880.
41. Poznanski A.K., Werder E.A., Giedion A., et al. The pattern of shortening of the bones of the hand in PHP and PPHP-A comparison with brachydactyly E, Turner Syndrome, and acrodysostosis. Radiology 1977, 123:707-718.
42. Archibald R.M., Finby N., De Vito F. Endocrine significance of short metacarpals. J Clin Endocrinol Metab 1959, 19:1312-1322.
43. Linglart A., Mahon M.J., Kerachian M.A., et al. Coding GNAS mutations leading to hormone resistance impair in vitro agonist- and cholera toxin-induced adenosine cyclic 3',5'-monophosphate formation mediated by human XLas. Endocrinology 2006, 147:2253-2262.
44. Lee H., Graham J.M., Rimoin D.L., et al. Exome sequencing identifies PDE4D mutations in acrodysostosis. Am J Hum Genet 2012, 90:746-751.
45. Michot C., Le Goff C., Goldenberg A., et al. Exome sequencing identifies PDE4D mutations as another cause of acrodysostosis. Am J Hum Genet 2012, 90:740-745.
46. Williams S.R., Aldred M.A., Der Kaloustian V.M., et al. Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems. Am J Hum Genet 2010, 87:219-228.
47. Levine M.A., Downs R.W., Moses A.M., et al. Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein. Am J Med 1983, 74:545-556.
48. Mallet E., Carayon P., Amr S., et al. Coupling defect of thyrotropin receptor and adenylate cyclase in a pseudohypoparathyroid patient. J Clin Endocrinol Metab 1982, 54:1028-1032.
49. Yu D., Yu S., Schuster V., et al. Identification of two novel deletion mutations within the Gs alpha gene (GNAS1) in Albright hereditary osteodystrophy. J Clin Endocrinol Metab 1999, 84:3254-3259.
50. Levine M.A., Jap T.S., Hung W. Infantile hypothyroidism in two sibs: an unusual presentation of pseudohypoparathyroidism type Ia. J Pediatr 1985, 107:919-922.
51. Weisman Y., Golander A., Spirer Z., Farfel Z. Pseudohypoparathyroidism type 1a presenting as congenital hypothyroidism. J Pediatr 1985, 107:413-415.
52. Yokoro S., Matsuo M., Ohtsuka T., Ohzeki T. Hyperthyrotropinemia in a neonate with normal thyroid hormone levels: the earliest diagnostic clue for pseudohypoparathyroidism. Biol Neonate 1990, 58:69-72.
53. Wolfsdorf J.I., Rosenfield R.L., Fang V.S., et al. Partial gonadotrophin-resistance in pseudohypoparathyroidism. Acta Endocrinol (Copenh) 1978, 88:321-328.
54. Mantovani G., Maghnie M., Weber G., et al. Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type Ia: new evidence for imprinting of the Gs alpha gene. J Clin Endocrinol Metab 2003, 88:4070-4074.
55. Germain-Lee E.L., Groman J., Crane J.L., et al. Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance. J Clin Endocrinol Metab 2003, 88:4059-4069.
56. Moses A.M., Weinstock R.S., Levine M.A., Breslau N.A. Evidence for normal antidiuretic responses to endogenous and exogenous arginine vasopressin in patients with guanine nucleotide-binding stimulatory protein-deficient pseudohypoparathyroidism. J Clin Endocrinol Metab 1986, 62:221-224.
57. Stirling H.F., Barr D.G.D., Kelnar C.J.H. Familial growth hormone releasing factor deficiency in pseudohypoparathyroidism. Arch Dis Child 1991, 66:533-535.
58. Namnoum A.B., Merriam G.R., Moses A.M., Levine M.A. Reproductive dysfunction in women with Albright's hereditary osteodystrophy. J Clin Endocrinol Metab 1998, 83:824-829.
59. s deficiency. G proteins, receptors, and disease 1998, 23-56. Humana Press, Totowa, New Jersey. A.M. Spiegel (Ed.).
60. Levine M.A. Pseudohypoparathyroidism: from bedside to bench and back. J Bone Miner Res 1999, 14:1255-1260.
61. Weinstein L.S., Gejman P.V., Friedman E., et al. Mutations of the Gs alpha-subunit gene in Albright hereditary osteodystrophy detected by denaturing gradient gel electrophoresis. Proc Natl Acad Sci U S A 1990, 87:8287-8290.
62. Patten J.L., Johns D.R., Valle D., et al. Mutation in the gene encoding the stimulatory G protein of adenylate cyclase in Albright's hereditary osteodystrophy. New Engl J Med 1990, 322:1412-1419.
63. Ma Y.C., Huang J., Ali S., et al. Src tyrosine kinase is a novel direct effector of G proteins. Cell 2000, 102:635-646.
64. Yatani A., Imoto Y., Codina J., et al. The stimulatory G protein of adenylyl cyclase, Gs, also stimulates dihydropyridine-sensitive Ca2+ channels. Evidence for direct regulation independent of phosphorylation by cAMP-dependent protein kinase or stimulation by a dihydropyridine agonist. J Biol Chem 1988, 263:9887-9895.
65. Mattera R., Graziano M.P., Yatani A., et al. Splice variants of the alpha subunit of the G protein Gs activate both adenylyl cyclase and calcium channels. Science 1989, 243:804-807.
66. Aldred M.A., Aftimos S., Hall C., et al. Constitutional deletion of chromosome 20q in two patients affected with albright hereditary osteodystrophy. Am J Med Genet 2002, 113:167-172.
67. Levine M.A., Jap T.S., Mauseth R.S., et al. Activity of the stimulatory guanine nucleotide-binding protein is reduced in erythrocytes from patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism: Biochemical, endocrine, and genetic analysis of Albright's hereditary osteodystrophy in six kindreds. J Clin Endocrinol Metab 1986, 62:497-502.
68. Miric A., Vechio J.D., Levine M.A. Heterogeneous mutations in the gene encoding the alpha-subunit of the stimulatory G protein of adenylyl cyclase in Albright hereditary osteodystrophy. J Clin Endocrinol Metab 1993, 76:1560-1568.
69. Farfel Z., Bourne H.R. Deficient activity of receptor-cyclase coupling protein in platelets of patients with pseudohypoparathyroidism. J Clin Endocrinol Metab 1980, 51:1202-1204.
70. Farfel Z., Brothers V.M., Brickman A.S., et al. Pseudohypoparathyroidism: inheritance of deficient receptor-cyclase coupling activity. Proc Natl Acad Sci U S A 1981, 78:3098-3102.
71. Bourne H.R., Kaslow H.R., Brickman A.S., Farfel Z. Fibroblast defect in pseudohypoparathyroidism, type I: reduced activity of receptor-cyclase coupling protein. J Clin Endocrinol Metab 1981, 53:636-640.
72. Spiegel A.M., Levine M.A., Aurbach G.D., et al. Deficiency of hormone receptor-adenylate cyclase coupling protein: basis for hormone resistance in pseudohypoparathyroidism. Am J Physiol 1982, 243:E37-E42.
73. Motulsky H.J., Hughes R.J., Brickman A.S., et al. Platelets of pseudohypoparathyroid patients: evidence that distinct receptor-cyclase coupling proteins mediate stimulation and inhibition of adenylate cyclase. Proc Natl Acad Sci U S A 1982, 79:4193-4197.
74. Farfel Z., Abood M.E., Brickman A.S., Bourne H.R. Deficient activity of receptor-cyclase coupling protein is transformed lymphoblasts of patients with pseudohypoparathyroidism, type I. J Clin Endocrinol Metab 1982, 55:113-117.
75. Levine M.A., Eil C., Downs R.W., Spiegel A.M. Deficient guanine nucleotide regulatory unit activity in cultured fibroblast membranes from patients with pseudohypoparathyroidism type I a cause of impaired synthesis of 3',5'-cyclic AMP by intact and broken cells. J Clin Invest 1983, 72:316-324.
76. Levine M.A., Ahn T.G., Klupt S.F., et al. Genetic deficiency of the alpha subunit of the guanine nucleotide-binding protein Gs as the molecular basis for Albright hereditary osteodystrophy. Proc Natl Acad Sci U S A 1988, 85:617-621.
77. Patten J.L., Levine M.A. Immunochemical analysis of the a-subunit of the stimulatory G-protein of adenylyl cyclase in patients with Albright's hereditary osteodystrophy. J Clin Endocrinol Metab 1990, 71:1208-1214.
78. Carter A., Bardin C., Collins R., et al. Reduced expression of multiple forms of the a subunit of the stimulatory GTP-binding protein in pseudohypoparathyroidism type Ia. Proc Natl Acad Sci U S A 1987, 84:7266-7269.
79. Farfel Z., Brickman A.S., Kaslow H.R., et al. Defect of receptor-cyclase coupling protein in pseudohypoparathyroidism. N Engl J Med 1980, 303:237-242.
80. Levine M.A., Downs R.W., Singer M., et al. Deficient activity of guanine nucleotide regulatory protein in erythrocytes from patients with pseudohypoparathyroidism. Biochem Biophys Res Commun 1980, 94:1319-1324.
81. Downs R.W., Levine M.A., Drezner M.K., et al. Deficient adenylate cyclase regulatory protein in renal membranes from a patient with pseudohypoparathyroidism. J Clin Invest 1983, 71:231-235.
82. Freson K., Izzi B., Labarque V., et al. GNAS defects identified by stimulatory G protein alpha-subunit signalling studies in platelets. J Clin Endocrinol Metab 2008, 93:4851-4859.
83. Iiri T., Herzmark P., Nakamoto J.M., et al. Rapid GDP release from Gs in patients with gain and loss of function. Nature 1994, 371:164-168.
84. Nakamoto J.M., Zimmerman D., Jones E.A., et al. Concurrent hormone resistance (pseudohypoparathyroidism type Ia) and hormone independence (testotoxicosis) caused by a unique mutation in the G alpha s gene. Biochem Mol Med 1996, 58:18-24.
85. Makita N., Sato J., Rondard P., et al. Human G(salpha) mutant causes pseudohypoparathyroidism type Ia/neonatal diarrhea, a potential cell-specific role of the palmitoylation cycle. Proc Natl Acad Sci U S A 2007, 104:17424-17429.
86. Freson K., Izzi B., Jaeken J., et al. Compound heterozygous mutations in the GNAS gene of a boy with morbid obesity, thyroid-stimulating hormone resistance, pseudohypoparathyroidism, and a prothrombotic state. J Clin Endocrinol Metab 2008, 93:4844-4849.
87. Linglart A., Carel J.C., Garabedian M., et al. GNAS1 lesions in pseudohypoparathyroidism Ia and Ic: genotype phenotype relationship and evidence of the maternal transmission of the hormonal resistance. J Clin Endocrinol Metab 2002, 87:189-197.
88. Gejman P.V., Weinstein L.S., Martinez M., et al. Genetic mapping of the Gs-a subunit gene (GNAS1) to the distal long arm of chromosome 20 using a polymorphism detected by denaturing gradient gel electrophoresis. Genomics 1991, 9:782-783.
89. Rao V.V., Schnittger S., Hansmann I. G protein Gs alpha (GNAS 1), the probable candidate gene for Albright hereditary osteodystrophy, is assigned to human chromosome 20q12-q13.2. Genomics 1991, 10:257-261.
90. Levine M.A., Modi W.S., O'Brien S.J. Mapping of the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase (GNAS1) to 20q13.2---q13.3 in human by in situ hybridization. Genomics 1991, 11:478-479.
91. Kozasa T., Itoh H., Tsukamoto T., Kaziro Y. Isolation and characterization of the human Gsa gene. Proc Natl Acad Sci U S A 1988, 85:2081-2085.
92. Bray P., Carter A., Simons C., et al. Human cDNA clones for four species of G alpha s signal transduction protein. Proc Natl Acad Sci U S A 1986, 83:8893-8897.
93. Robishaw J.D., Smigel M.D., Gilman A.G. Molecular basis for two forms of the G protein that stimulates adenylate cyclase. J Biol Chem 1986, 261:9587-9590.
94. Sternweis P.C., Northup J.K., Smigel M.D., Gilman A.G. The regulatory component of adenylate cyclase. Purification and properties. J Biol Chem 1981, 256:11517-11526.
95. Walseth T.F., Zhang H.J., Olson L.K., et al. Increase in Gs and cyclic AMP generation in HIT cells. Evidence that the 45-kDa alpha-subunit of Gs has greater functional activity than the 52-kDa alpha-subunit. J Biol Chem 1989, 264:21106-21111.
96. Graziano M.P., Freissmuth M., Gilman A.G. Expression of Gs alpha in Escherichia coli. Purification and properties of two forms of the protein. J Biol Chem 1989, 264:409-418.
97. Seifert R., Wenzel-Seifert K., Lee T.W., et al. Different effects of Gsalpha splice variants on beta2-adrenoreceptor-mediated signaling. The beta2-adrenoreceptor coupled to the long splice variant of Gsalpha has properties of a constitutively active receptor. J Biol Chem 1998, 273:5109-5116.
98. Kvapil P., Novotny J., Svoboda P., Ransnas L.A. The short and long forms of the alpha subunit of the stimulatory guanine-nucleotide-binding protein are unequally redistributed during (-)-isoproterenol-mediated desensitization of intact S49 lymphoma cells. Eur J Biochem 1994, 226:193-199.
99. el Jamali A., Rachdaoui N., Jacquemin C., Correze C. Long-term effect of forskolin on the activation of adenylyl cyclase in astrocytes. J Neurochem 1996, 67:2532-2539.
100. Bourgeois C., Duc-Goiran P., Robert B., et al. G protein expression in human fetoplacental vascularization. Functional evidence for Gs alpha and Gi alpha subunits. J Mol Cell Cardiol 1996, 28:1009-1021.
101. Thiele S., Werner R., Ahrens W., et al. A disruptive mutation in exon 3 of the GNAS gene with albright hereditary osteodystrophy, normocalcemic pseudohypoparathyroidism, and selective long transcript variant Gsalpha-L deficiency. J Clin Endocrinol Metab 2007, 92:1764-1768.
102. Ischia R., Lovisetti-Scamihorn P., Hogue-Angeletti R., et al. Molecular cloning and characterization of NESP55, a novel chromogranin-like precursor of a peptide with 5-HT1B receptor antagonist activity. J Biol Chem 1997, 272:11657-11662.
103. Hayward B.E., Moran V., Strain L., Bonthron D.T. Bidirectional imprinting of a single gene: GNAS1 encodes maternally, paternally, and biallelically derived proteins. Proc Natl Acad Sci U S A 1998, 95:15475-15480.
104. Peters J., Wroe S.F., Wells C.A., et al. A cluster of oppositely imprinted transcripts at the Gnas locus in the distal imprinting region of mouse chromosome 2. Proc Natl Acad Sci U S A 1999, 96:3830-3835.
105. Lovisetti-Scamihorn P., Fischer-Colbrie R., Leitner B., et al. Relative amounts and molecular forms of NESP55 in various bovine tissues. Brain Res 1999, 829:99-106.
106. Weiss U., Ischia R., Eder S., et al. Neuroendocrine secretory protein 55 (NESP55): alternative splicing onto transcripts of the GNAS gene and posttranslational processing of a maternally expressed protein. Neuroendocrinology 2000, 71:177-186.
107. Bauer R., Weiss C., Marksteiner J., et al. The new chromogranin-like protein NESP55 is preferentially localized in adrenaline-synthesizing cells of the bovine and rat adrenal medulla. Neurosci Lett 1999, 263:13-16.
108. Li J.Y., Lovisetti-Scamihorn P., Fischer-Colbrie R., et al. Distribution and intraneuronal trafficking of a novel member of the chromogranin family, NESP55, in the rat peripheral nervous system. Neuroscience 2002, 110:731-745.
109. Fischer-Colbrie R., Eder S., Lovisetti-Scamihorn P., et al. Neuroendocrine secretory protein 55: a novel marker for the constitutive secretory pathway. Ann N Y Acad Sci 2002, 971:317-322.
110. Plagge A., Isles A.R., Gordon E., et al. Imprinted Nesp55 influences behavioral reactivity to novel environments. Mol Cell Biol 2005, 25:3019-3026.
111. Kehlenbach R.H., Matthey J., Huttner W.B. XLás is a new type of G protein (Erratum in Nature 1995 375:253). Nature 1994, 372:804-809.
112. Hayward B., Kamiya M., Strain L., et al. The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins. Proc Natl Acad Sci U S A 1998, 95:10038-10043.
113. Pasolli H., Klemke M., Kehlenbach R., et al. Characterization of the extra-large G protein alpha-subunit XLalphas. I Tissue distribution and subcellular localization. J Biol Chem 2000, 275:33622-33632.
114. Pasolli H., Huttner W. Expression of the extra-large G protein alpha-subunit XLalphas in neuroepithelial cells and young neurons during development of the rat nervous system. Neurosci Lett 2001, 301:119-122.
115. Liu Z., Segawa H., Aydin C., et al. Transgenic overexpression of the extra-large Gs(alpha)variant XL(alpha)s enhances Gs(alpha)-mediated responses in the mouse renal proximal tubule in vivo. Endocrinology 2011, 152:1222-1233.
116. Pignolo R.J., Xu M., Russell E., et al. Heterozygous inactivation of Gnas in adipose-derived mesenchymal progenitor cells enhances osteoblast differentiation and promotes heterotopic ossification. J Bone Miner Res 2011, 26:2647-2655.
117. Krechowec S.O., Burton K.L., Newlaczyl A.U., et al. Postnatal changes in the expression pattern of the imprinted signalling protein XLalphas underlie the changing phenotype of deficient mice. PLoS One 2012, 7:e29753.
118. Plagge A., Gordon E., Dean W., et al. The imprinted signaling protein XLalphas is required for postnatal adaptation to feeding. Nat Genet 2004, 36:818-826.
119. Michienzi S., Cherman N., Holmbeck K., et al. GNAS transcripts in skeletal progenitors: evidence for random asymmetric allelic expression of Gs(alpha). Hum Mol Genet 2007, 16:1921-1930.
120. Mariot V., Wu J.Y., Aydin C., et al. Potent constitutive cyclic AMP-generating activity of XLalphas implicates this imprinted GNAS product in the pathogenesis of McCune-Albright Syndrome and fibrous dysplasia of bone. Bone 2011, 48:312-320.
121. Klemke M., Pasolli H., Kehlenbach R., et al. Characterization of the extra-large G protein alpha-subunit XLalphas. II Signal transduction properties. J Biol Chem 2000, 275:33633-33640.
122. Bastepe M., Gunes Y., Perez-Villamil B., et al. Receptor-Mediated adenylyl cyclase activation through XLalphas, the extra-large variant of the stimulatory G Protein alpha-subunit. Mol Endocrinol 2002, 16:1912-1919.
123. Liu Z., Turan S., Wehbi V.L., et al. Extra-long Galphas variant XLalphas protein escapes activation-induced subcellular redistribution and is able to provide sustained signaling. J Biol Chem 2011, 286:38558-38569.
124. Chen M., Gavrilova O., Liu J., et al. Alternative Gnas gene products have opposite effects on glucose and lipid metabolism. Proc Natl Acad Sci U S A 2005, 102:7386-7391.
125. Germain-Lee E.L., Schwindinger W., Crane J.L., et al. A mouse model of Albright hereditary osteodystrophy generated by targeted disruption of exon 1 of the Gnas gene. Endocrinology 2005, 146:4697-4709.
126. Xie T., Plagge A., Gavrilova O., et al. The alternative stimulatory G protein alpha-subunit XLalphas is a critical regulator of energy and glucose metabolism and sympathetic nerve activity in adult mice. J Biol Chem 2006, 281:18989-18999.
127. Eaton S.A., Williamson C.M., Ball S.T., et al. New mutations at the imprinted Gnas cluster show gene dosage effects of Gsalpha in postnatal growth and implicate XLalphas in bone and fat metabolism but not in suckling. Mol Cell Biol 2012, 32:1017-1029.
128. Swaroop A., Agarwal N., Gruen J.R., et al. Differential expression of novel Gs alpha signal transduction protein cDNA species. Nucleic Acids Res 1991, 19:4725-4729.
129. sa mRNA. J Biol Chem 1990, 265:8458-8462.
130. Puzhko S., Goodyer C.G., Mohammad A.K., et al. Parathyroid hormone signaling via Galphas is selectively inhibited by an NH(2)-terminally truncated Galphas: Implications for pseudohypoparathyroidism. J Bone Miner Res 2011, 26:2473-2485.
131. Hayward B., Bonthron D. An imprinted antisense transcript at the human GNAS1 locus. Hum Mol Genet 2000, 9:835-841.
132. Wroe S.F., Kelsey G., Skinner J.A., et al. An imprinted transcript, antisense to Nesp, adds complexity to the cluster of imprinted genes at the mouse Gnas locus. Proc Natl Acad Sci U S A 2000, 97:3342-3346.
133. Bastepe M., Fröhlich L.F., Linglart A., et al. Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type-Ib. Nat Genet 2005, 37:25-37.
134. Williamson C.M., Turner M.D., Ball S.T., et al. Identification of an imprinting control region affecting the expression of all transcripts in the Gnas cluster. Nat Genet 2006, 38:350-355.
135. Coombes C., Arnaud P., Gordon E., et al. Epigenetic properties and identification of an imprint mark in the Nesp-Gnasxl domain of the mouse Gnas imprinted locus. Mol Cell Biol 2003, 23:5475-5488.
136. Liu J., Yu S., Litman D., et al. Identification of a methylation imprint mark within the mouse gnas locus. Mol Cell Biol 2000, 20:5808-5817.
137. Williamson C.M., Ball S.T., Nottingham W.T., et al. A cis-acting control region is required exclusively for the tissue-specific imprinting of Gnas. Nat Genet 2004, 36:894-899.
138. Liu J., Chen M., Deng C., et al. Identification of the control region for tissue-specific imprinting of the stimulatory G protein alpha-subunit. Proc Natl Acad Sci U S A 2005, 102:5513-5518.
139. Zheng H., Radeva G., McCann J.A., et al. Gas transcripts are biallelically expressed in the human kidney cortex: implications for pseudohypoparathyroidism type Ib. J Clin Endocrinol Metab 2001, 86:4627-4629.
140. Campbell R., Gosden C.M., Bonthron D.T. Parental origin of transcription from the human GNAS1 gene. J Med Genet 1994, 31:607-614.
141. Mantovani G., Bondioni S., Locatelli M., et al. Biallelic expression of the Gsalpha gene in human bone and adipose tissue. J Clin Endocrinol Metab 2004, 89:6316-6319.
142. sa gene. Proc Natl Acad Sci U S A 1998, 95:8715-8720.
143. Hayward B., Barlier A., Korbonits M., et al. Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 2001, 107:R31-R36.
144. Mantovani G., Ballare E., Giammona E., et al. The Gsalpha gene: predominant maternal origin of transcription in human thyroid gland and gonads. J Clin Endocrinol Metab 2002, 87:4736-4740.
145. Sakamoto A., Liu J., Greene A., et al. Tissue-specific imprinting of the G protein Gsalpha is associated with tissue-specific differences in histone methylation. Hum Mol Genet 2004, 13:819-828.
146. Albright F., Forbes A.P., Henneman P.H. Pseudo-pseudohypoparathyroidism. Trans Assoc Am Physicians 1952, 65:337-350.
147. Davies A.J., Hughes H.E. Imprinting in Albright's hereditary osteodystrophy. J Med Genet 1993, 30:101-103.
148. Lebrun M., Richard N., Abeguile G., et al. Progressive osseous heteroplasia: a model for the imprinting effects of GNAS inactivating mutations in humans. J Clin Endocrinol Metab 2010, 95:3028-3038.
149. Liu J.J., Russell E., Zhang D., et al. Paternally inherited gsalpha mutation impairs adipogenesis and potentiates a lean phenotype in vivo. Stem Cells 2012, 30:1477-1485.
150. Richard N., Molin A., Coudray N., et al. Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLalphas in fetal development. J Clin Endocrinol Metab 2013, 98:E1549-E1556.
151. Turan S., Fernandez-Rebollo E., Aydin C., et al. Postnatal establishment of allelic Gαs silencing as a plausible explanation for delayed onset of parathyroid hormone-resistance due to heterozygous Gαs disruption. J Bone Miner Res 2014, 29:749-760.
152. Kronenberg H.M. Developmental regulation of the growth plate. Nature 2003, 423:332-336.
153. Bastepe M., Weinstein L.S., Ogata N., et al. Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo. Proc Natl Acad Sci U S A 2004, 101:14794-14799.
154. Long D.N., McGuire S., Levine M.A., et al. Body mass index differences in pseudohypoparathyroidism type 1a versus pseudopseudohypoparathyroidism may implicate paternal imprinting of Galpha(s) in the development of human obesity. J Clin Endocrinol Metab 2007, 92:1073-1079.
155. Mouallem M., Shaharabany M., Weintrob N., et al. Cognitive impairment is prevalent in pseudohypoparathyroidism type Ia, but not in pseudopseudohypoparathyroidism: possible cerebral imprinting of Gsalpha. Clin Endocrinol (Oxf) 2008, 68:233-239.
156. Kaplan F.S., Craver R., MacEwen G.D., et al. Progressive osseous heteroplasia: a distinct developmental disorder of heterotopic ossification. Two new case reports and follow-up of three previously reported cases. J Bone Joint Surg Am 1994, 76:425-436.
157. Kaplan F.S., Shore E.M. Progressive osseous heteroplasia. J Bone Miner Res 2000, 15:2084-2094.
158. Buyse G., Silberstein J., Goemans N., Casaer P. Fibrodysplasia ossificans progressiva: still turning into wood after 300 years?. Eur J Pediatr 1995, 154:694-699.
159. Shore E.M., Kaplan F.S. Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP). Bone 2008, 43:427-433.
160. Eddy M.C., De Beur S.M., Yandow S.M., et al. Deficiency of the alpha-subunit of the stimulatory G protein and severe extraskeletal ossification. J Bone Miner Res 2000, 15:2074-2083.
161. Yeh G.L., Mathur S., Wivel A., et al. GNAS1 mutation and Cbfa1 misexpression in a child with severe congenital platelike osteoma cutis. J Bone Miner Res 2000, 15:2063-2073.
162. Shore E.M., Ahn J., Jan de Beur S., et al. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 2002, 346:99-106.
163. Weinstein L.S., Yu S., Warner D.R., Liu J. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev 2001, 22:675-705.
164. Lietman S.A., Ding C., Cooke D.W., Levine M.A. Reduction in Gsalpha induces osteogenic differentiation in human mesenchymal stem cells. Clin Orthop Relat Res 2005, 231-238.
165. Zhao Y., Ding S. A high-throughput siRNA library screen identifies osteogenic suppressors in human mesenchymal stem cells. Proc Natl Acad Sci U S A 2007, 104:9673-9678.
166. Bertaux K., Broux O., Chauveau C., et al. Runx2 regulates the expression of GNAS on SaOs-2 cells. Bone 2006, 38:943-950.
167. Adegbite N.S., Xu M., Kaplan F.S., et al. Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification. Am J Med Genet A 2008, 146A:1788-1796.
168. Cairns D.M., Pignolo R.J., Uchimura T., et al. Somitic disruption of GNAS in chick embryos mimics progressive osseous heteroplasia. J Clin Invest 2013, 123:3624-3633.
169. Peterman M.G., Garvey J.L. Pseudohypoparathyroidism; case report. Pediatrics 1949, 4:790.
170. Reynolds T.B., Jacobson G., Edmondson H.A., et al. Pseudohypoparathyroidism: report of a case showing bony demineralization. J Clin Endocrinol Metab 1952, 12:560.
171. Elrick H., Albright F., Bartter F.C., et al. Further studies on pseudo-hypoparathyroidism: report of four new cases. Acta Endocrinol 1950, 5:199-225.
172. Costello J.M., Dent C.E. Hypo-hyperparathyroidism. Arch Dis Child 1963, 38:397-407.
173. Allen E.H., Millard F.J.C., Nassim J.R. Hypo-hyperparathyroidism. Arch Dis Child 1968, 43:295-301.
174. Frame B., Hanson C.A., Frost H.M., et al. Renal resistance to parathyroid hormone with osteitis fibrosa: "pseudohypohyperparathyroidism.". Am J Med 1972, 52:311-321.
175. Jüppner H., Schipani E., Bastepe M., et al. The gene responsible for pseudohypoparathyroidism type Ib is paternally imprinted and maps in four unrelated kindreds to chromosome 20q13.3. Proc Natl Acad Sci U S A 1998, 95:11798-11803.
176. Bastepe M., Lane A.H., Jüppner H. Paternal uniparental isodisomy of chromosome 20q (patUPD20q)-and the resulting changes in GNAS1 methylation-as a plausible cause of pseudohypoparathyroidism. Am J Hum Genet 2001, 68:1283-1289.
177. Liu J., Erlichman B., Weinstein L.S. The stimulatory G protein a-subunit Gsa is imprinted in human thyroid glands: implications for thyroid function in pseudohypoparathyroidism types 1A and 1B. J Clin Endocrinol Metab 2003, 88:4336-4341.
178. Mantovani G., Bondioni S., Linglart A., et al. Genetic analysis and evaluation of resistance to thyrotropin and growth hormone-releasing hormone in pseudohypoparathyroidism type Ib. J Clin Endocrinol Metab 2007, 92:3738-3742.
179. Laspa E., Bastepe M., Jüppner H., Tsatsoulis A. Phenotypic and molecular genetic aspects of pseudohypoparathyroidism type Ib in a Greek kindred: evidence for enhanced uric acid excretion due to parathyroid hormone resistance. J Clin Endocrinol Metab 2004, 89:5942-5947.
180. Pepersack T., Jabbour N., Fuss M., et al. Hyperuricemia and renal handling of urate in primary hyperparathyroidism. Nephron 1989, 53:349-352.
181. Westerdahl J., Valdemarsson S., Lindblom P., Bergenfelz A. Urate and arteriosclerosis in primary hyperparathyroidism. Clin Endocrinol (Oxf) 2001, 54:805-811.
182. Wu W.I., Schwindinger W.F., Aparicio L.F., Levine M.A. Selective resistance to parathyroid hormone caused by a novel uncoupling mutation in the carboxyl terminus of Gas: A cause of pseudohypoparathyroidism type Ib. J Biol Chem 2001, 276:165-171.
183. Silve C., Santora A., Breslau N., et al. Selective resistance to parathyroid hormone in cultured skin fibroblasts from patients with pseudohypoparathyroidism type Ib. J Clin Endocrinol Metab 1986, 62:640-644.
184. Schipani E., Weinstein L.S., Bergwitz C., et al. Pseudohypoparathyroidism type Ib is not caused by mutations in the coding exons of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene. J Clin Endocrinol Metab 1995, 80:1611-1621.
185. Suarez F., Lebrun J.J., Lecossier D., et al. Expression and modulation of the parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid in skin fibroblasts from patients with type Ib pseudohypoparathyroidism. J Clin Endocrinol Metab 1995, 80:965-970.
186. Fukumoto S., Suzawa M., Takeuchi Y., et al. Absence of mutations in parathyroid hormone (PTH)/PTH-related protein receptor complementary deoxyribonucleic acid in patients with pseudohypoparathyroidism type Ib. J Clin Endocrinol Metab 1996, 81:2554-2558.
187. Jan de Beur S., Ding C., LaBuda M., et al. Pseudohypoparathyroidism 1b: exclusion of parathyroid hormone and its receptors as candidate disease genes. J Clin Endocrinol Metab 2000, 85:2239-2246.
188. Blomstrand S., Claësson I., Säve-Söderbergh J. A case of lethal congenital dwarfism with accelerated skeletal maturation. Pediatr Radiol 1985, 15:141-143.
189. Duchatelet S., Ostergaard E., Cortes D., et al. Recessive mutations in PTHR1 cause contrasting skeletal dysplasias in Eiken and Blomstrand syndromes. Hum Mol Genet 2005, 14:1-5.
190. Decker E., Stellzig-Eisenhauer A., Fiebig B.S., et al. PTHR1 loss-of-function mutations in familial, nonsyndromic primary failure of tooth eruption. Am J Hum Genet 2008, 83:781-786.
191. Stellzig-Eisenhauer A., Decker E., Meyer-Marcotty P., et al. Primary failure of eruption (PFE)-clinical and molecular genetics analysis. J Orofac Orthop 2010, 71:6-16.
192. Frazier-Bowers S.A., Simmons D., Wright J.T., et al. Primary failure of eruption and PTH1R: the importance of a genetic diagnosis for orthodontic treatment planning. Am J Orthod Dentofacial Orthop 2010, 137. 160 e161-e167; discussion 160-161.
193. Yamaguchi T., Hosomichi K., Narita A., et al. Exome resequencing combined with linkage analysis identifies novel PTH1R variants in primary failure of tooth eruption in Japanese. J Bone Miner Res 2011, 26:1655-1661.
194. Liu J., Litman D., Rosenberg M., et al. A GNAS1 imprinting defect in pseudohypoparathyroidism type IB. J Clin Invest 2000, 106:1167-1174.
195. Jan de Beur S., Ding C., Germain-Lee E., et al. Discordance between genetic and epigenetic defects in pseudohypoparathyroidism type 1b revealed by inconsistent loss of maternal imprinting at GNAS1. Am J Hum Genet 2003, 73:314-322.
196. Bastepe M., Altug-Teber O., Agarwal C., et al. Paternal uniparental isodisomy of the entire chromosome 20 as a molecular cause of pseudohypoparathyroidism type Ib (PHP-Ib). Bone 2011, 48:659-662.
197. Fernandez-Rebollo E., Lecumberri B., Garin I., et al. New mechanisms involved in paternal 20q disomy associated with pseudohypoparathyroidism. Eur J Endocrinol 2010, 163:953-962.
198. Lecumberri B., Fernandez-Rebollo E., Sentchordi L., et al. Coexistence of two different pseudohypoparathyroidism subtypes (Ia and Ib) in the same kindred with independent Gs(alpha) coding mutations and GNAS imprinting defects. J Med Genet 2010, 47:276-280.
199. Dixit A., Chandler K.E., Lever M., et al. Pseudohypoparathyroidism type 1b due to paternal uniparental disomy of chromosome 20q. J Clin Endocrinol Metab 2013, 98:E103-108.
200. Bastepe M., Fröhlich L.F., Hendy G.N., et al. Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest 2003, 112:1255-1263.
201. Liu J., Nealon J.G., Weinstein L.S. Distinct patterns of abnormal GNAS imprinting in familial and sporadic pseudohypoparathyroidism type IB. Hum Mol Genet 2005, 14:95-102.
202. de Nanclares G.P., Fernandez-Rebollo E., Santin I., et al. Epigenetic defects of GNAS in patients with pseudohypoparathyroidism and mild features of Albright's hereditary osteodystrophy. J Clin Endocrinol Metab 2007, 92:2370-2373.
203. Elli F.M., de Sanctis L., Peverelli E., et al. Autosomal dominant pseudohypoparathyroidism type Ib: a novel inherited deletion ablating STX16 causes loss of imprinting at the A/B DMR. J Clin Endocrinol Metab 2014, 99:E724-E728.
204. Fröhlich L.F., Bastepe M., Ozturk D., et al. Lack of Gnas epigenetic changes and pseudohypoparathyroidism type Ib in mice with targeted disruption of syntaxin-16. Endocrinology 2007, 148:2925-2935.
205. Chillambhi S, Turan S, Hwang D-Y, et al. Deletion of the GNAS antisense transcript results in parent-of-origin specific GNAS imprinting defects and phenotypes including PTH-resistance (Abstract No. 1052). 30th Annual Meeting of The American Society of Bone and Mineral Research. Montreal. 2008.
206. Richard N., Abeguile G., Coudray N., et al. A new deletion ablating NESP55 causes loss of maternal imprint of A/B GNAS and autosomal dominant pseudohypoparathyroidism type Ib. J Clin Endocrinol Metab 2012, 97:E863-E867.
207. Chotalia M., Smallwood S.A., Ruf N., et al. Transcription is required for establishment of germline methylation marks at imprinted genes. Genes Dev 2009, 23:105-117.
208. Fernandez-Rebollo E., Perez de Nanclares G., Lecumberri B., et al. Exclusion of the GNAS locus in PHP-Ib patients with broad GNAS methylation changes: evidence for an autosomal recessive form of PHP-Ib?. J Bone Miner Res 2011, 26:1854-1863.
209. Cavaco B.M., Tomaz R.A., Fonseca F., et al. Clinical and genetic characterization of Portuguese patients with pseudohypoparathyroidism type Ib. Endocrine 2010, 37:408-414.
210. Mackay D.J., Callaway J.L., Marks S.M., et al. Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFP57. Nat Genet 2008, 40:949-951.
211. Bliek J., Verde G., Callaway J., et al. Hypomethylation at multiple maternally methylated imprinted regions including PLAGL1 and GNAS loci in Beckwith-Wiedemann syndrome. Eur J Hum Genet 2009, 17:611-619.
212. Perez-Nanclares G., Romanelli V., Mayo S., et al. Detection of hypomethylation syndrome among patients with epigenetic alterations at the GNAS locus. J Clin Endocrinol Metab 2012, 97:E1060-E1067.
213. Mariot V., Maupetit-Mehouas S., Sinding C., et al. A maternal epimutation of GNAS leads to Albright osteodystrophy and parathyroid hormone resistance. J Clin Endocrinol Metab 2008, 93:661-665.
214. Mantovani G., de Sanctis L., Barbieri A.M., et al. Pseudohypoparathyroidism and GNAS epigenetic defects: clinical evaluation of albright hereditary osteodystrophy and molecular analysis in 40 patients. J Clin Endocrinol Metab 2010, 95:651-658.
215. Sanchez J., Perera E., Jan de Beur S., et al. Madelung-like deformity in pseudohypoparathyroidism type 1b. J Clin Endocrinol Metab 2011, 96:E1507-E1511.
216. Fernandez-Rebollo E., Garcia-Cuartero B., Garin I., et al. Intragenic GNAS deletion involving exon A/B in pseudohypoparathyroidism type 1A resulting in an apparent loss of exon A/B methylation: potential for misdiagnosis of pseudohypoparathyroidism type 1B. J Clin Endocrinol Metab 2010, 95:765-771.
217. van Dop C. Pseudohypoparathyroidism: Clinical and molecular aspects. Semin Nephrol 1989, 9:168-178.
218. Kruse K., Kustermann W. Evidence for transient peripheral resistance to parathyroid hormone in premature infants. Acta Paediatr Scand 1987, 76:115-118.
219. Lee C.T., Tsai W.Y., Tung Y.C., Tsau Y.K. Transient pseudohypoparathyroidism as a cause of late-onset hypocalcemia in neonates and infants. J Formos Med Assoc 2008, 107:806-810.
220. Manzar S. Transient pseudohypoparathyroidism and neonatal seizure. J Trop Pediatr 2001, 47:113-114.
221. Guo J., Liu M., Yang D., et al. Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH. Endocrinology 2010, 151:3502-3513.
222. Guo J., Song L., Liu M., et al. Activation of a non-cAMP/PKA signaling pathway downstream of the PTH/PTHrP receptor is essential for a sustained hypophosphatemic response to PTH infusion in male mice. Endocrinology 2013, 154:1680-1689.
223. Kruse K., Kracht U., Wohlfart K., Kruse U. Biochemical markers of bone turnover, intact serum parathyroid horn and renal calcium excretion in patients with pseudohypoparathyroidism and hypoparathyroidism before and during vitamin D treatment. Eur J Pediatr 1989, 148:535-539.
224. Rao D.S., Parfitt A.M., Kleerekoper M., et al. Dissociation between the effects of endogenous parathyroid hormone on adenosine 3',5'-monophosphate generation and phosphate reabsorption in hypocalcemia due to vitamin D depletion: an acquired disorder resembling pseudohypoparathyroidism type II. J Clin Endocrinol Metab 1985, 61:285-290.
225. Srivastava T., Alon U.S. Stage I vitamin D-deficiency rickets mimicking pseudohypoparathyroidism type II. Clin Pediatr (Phila) 2002, 41:263-268.
226. Shriraam M., Bhansali A., Velayutham P. Vitamin D deficiency masquerading as pseudohypoparathyroidism type 2. J Assoc Physicians India 2003, 51:619-620.
227. Linglart A., Menguy C., Couvineau A., et al. Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance. N Engl J Med 2011, 364:2218-2226.
228. Reiter S. Acrodysostosis. A case of peripheral dysostosis, nasal hypoplasia, mental retardation and impaired hearing. Pediatr Radiol 1978, 7:53-55.
229. Robinow M., Pfeiffer R.A., Gorlin R.J., et al. Acrodysostosis. A syndrome of peripheral dysostosis, nasal hypoplasia, and mental retardation. Am J Dis Child 1971, 121:195-203.
230. Maroteaux P., Malamut G. Acrodysostosis. Presse Med 1968, 76:2189-2192.
231. Nagasaki K., Iida T., Sato H., et al. PRKAR1A mutation affecting cAMP-mediated G protein-coupled receptor signaling in a patient with acrodysostosis and hormone resistance. J Clin Endocrinol Metab 2012, 97:E1808-E1813.
232. Linglart A., Fryssira H., Hiort O., et al. PRKAR1A and PDE4D mutations cause acrodysostosis but two distinct syndromes with or without GPCR-signaling hormone resistance. J Clin Endocrinol Metab 2012, 97:E2328-E2338.
233. Muhn F., Klopocki E., Graul-Neumann L., et al. Novel mutations of the PRKAR1A gene in patients with acrodysostosis. Clin Genet 2013, 84:531-538.
234. Silve C., Jüppner H. Genetic disorders caused by mutations in the PTH/PTHrP receptor and downstream effector molecules. The parathyroids 2015, Elsevier, 587-605. J.P. Bilezikian (Ed.).
235. Lynch D.C., Dyment D.A., Huang L., et al. Identification of novel mutations confirms PDE4D as a major gene causing acrodysostosis. Hum Mutat 2013, 34:97-102.
236. Conti M., Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007, 76:481-511.
237. Mantovani G., Ferrante E., Giavoli C., et al. Recombinant human GH replacement therapy in children with pseudohypoparathyroidism type Ia: first study on the effect on growth. J Clin Endocrinol Metab 2010, 95:5011-5017.
238. Farfel Z. Pseudohypohyperparathyroidism-pseudohypoparathyroidism type Ib. J Bone Miner Res 1999, 14:1016.
239. Levine M. Hypoparathyroidism and pseudohypoparathyroidism. Endocrinology 2000, 1133-1153. Saunders, Philadelphia. 4th ed. L.J. De Groot, J. Jameson (Eds.).